Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does USTEKINUMAB Cause Insurance issue? 103 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 103 reports of Insurance issue have been filed in association with USTEKINUMAB (PYZCHIVA). This represents 0.1% of all adverse event reports for USTEKINUMAB.

103
Reports of Insurance issue with USTEKINUMAB
0.1%
of all USTEKINUMAB reports
1
Deaths
15
Hospitalizations

How Dangerous Is Insurance issue From USTEKINUMAB?

Of the 103 reports, 1 (1.0%) resulted in death, 15 (14.6%) required hospitalization, and 1 (1.0%) were considered life-threatening.

Is Insurance issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for USTEKINUMAB. However, 103 reports have been filed with the FAERS database.

What Other Side Effects Does USTEKINUMAB Cause?

Drug ineffective (12,471) Off label use (10,990) Product dose omission issue (9,405) Fatigue (5,457) Product use issue (5,008) Psoriasis (4,955) Pain (4,872) Rash (4,736) Crohn's disease (4,662) Arthralgia (4,608)

What Other Drugs Cause Insurance issue?

CERTOLIZUMAB PEGOL (1,210) HUMAN IMMUNOGLOBULIN G (1,090) LISDEXAMFETAMINE DIMESYLATE (590) RIFAXIMIN (577) LENALIDOMIDE (376) ARIPIPRAZOLE (345) HUMAN C1-ESTERASE INHIBITOR (295) HUMAN IMMUNOGLOBULIN G\HYALURONIDASE (253) AMPHETAMINE ASPARTATE\AMPHETAMINE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE (227) ETANERCEPT (220)

Which USTEKINUMAB Alternatives Have Lower Insurance issue Risk?

USTEKINUMAB vs USTEKINUMAB-STBA USTEKINUMAB vs VADADUSTAT USTEKINUMAB vs VALACYCLOVIR USTEKINUMAB vs VALBENAZINE USTEKINUMAB vs VALBENAZINE DITOSYLATE

Related Pages

USTEKINUMAB Full Profile All Insurance issue Reports All Drugs Causing Insurance issue USTEKINUMAB Demographics